{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:04:40Z","timestamp":1790935480542,"version":"4.1.0"},"reference-count":100,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T00:00:00Z","timestamp":1329782400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0031906","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T22:51:35Z","timestamp":1329864695000},"page":"e31906","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":100,"title":["A Novel Classification of Lung Cancer into Molecular Subtypes"],"prefix":"10.1371","volume":"7","author":[{"given":"Lisandra","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smruti J.","family":"Vidwans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Shrager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip A.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Otterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,2,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"A Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"ref2","article-title":"National Cancer Institute website."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.seminoncol.2011.01.012","article-title":"Personalized treatment of lung cancer.","volume":"38","author":"R Salgia","year":"2011","journal-title":"Semin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer.","volume":"353","author":"FA Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.","volume":"361","author":"TS Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.","volume":"363","author":"EL Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e18257","DOI":"10.1371\/journal.pone.0018257","article-title":"A melanoma molecular disease model.","volume":"6","author":"SJ Vidwans","year":"2011","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/JTO.0b013e31820a3a6b","article-title":"Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.","volume":"6","author":"V Ludovini","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.radonc.2005.06.024","article-title":"Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway.","volume":"76","author":"M Toulany","year":"2005","journal-title":"Radiother Oncol"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/jcp.22895","article-title":"Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)\/AKT pathways.","volume":"227","author":"JI Hanai","year":"2011","journal-title":"J Cell Physiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"30934","DOI":"10.1074\/jbc.M004112200","article-title":"Akt\/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation.","volume":"275","author":"J Okano","year":"2000","journal-title":"J Biol Chem"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0169-5002(03)00137-5","article-title":"Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.","volume":"41","author":"FR Hirsch","year":"2003","journal-title":"Lung Cancer"},{"key":"ref13","article-title":"National Comprehensive Cancer Network website."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12325-010-0103-9","article-title":"Mind-mapping for lung cancer: towards a personalized therapeutics approach.","volume":"28","author":"N Mollberg","year":"2011","journal-title":"Adv Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-09-0888","article-title":"Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.","volume":"15","author":"DM Jackman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.","volume":"362","author":"M Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0305-7372(10)70016-5","article-title":"Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.","volume":"36","author":"G Bronte","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"ref18","first-page":"Unit 10 11","article-title":"The Catalogue of Somatic Mutations in Cancer (COSMIC).","volume":"10","author":"SA Forbes","year":"2008","journal-title":"Curr Protoc Hum Genet Chapter"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/1078-0432.CCR-06-0714","article-title":"Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.","volume":"12","author":"T Kosaka","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.lungcan.2009.05.022","article-title":"Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.","volume":"68","author":"T Onitsuka","year":"2010","journal-title":"Lung Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.","volume":"17","author":"GR Oxnard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.","volume":"2","author":"W Pao","year":"2005","journal-title":"PLoS Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.","volume":"105","author":"CH Yun","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.","volume":"3","author":"LV Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2009.26.7278","article-title":"Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.","volume":"28","author":"TA Yap","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(00)04013-7","article-title":"Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey.","volume":"357","author":"I Roushdy-Hammady","year":"2001","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1158\/0008-5472.CAN-04-2219","article-title":"SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study.","volume":"65","author":"A Cristaudo","year":"2005","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1158\/0008-5472.CAN-04-2461","article-title":"Evidence against a role for SV40 in human mesothelioma.","volume":"65","author":"JJ Manfredi","year":"2005","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-10-1371","article-title":"Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.","volume":"16","author":"K Suda","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.7505","article-title":"Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.","volume":"29","author":"D Spigel","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","article-title":"A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.","volume":"425","author":"A Kamal","year":"2003","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1038\/sj.onc.1207529","article-title":"Molecular chaperones and the stress of oncogenesis.","volume":"23","author":"DD Mosser","year":"2004","journal-title":"Oncogene"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-07-5256","article-title":"NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.","volume":"68","author":"SA Eccles","year":"2008","journal-title":"Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/JTO.0b013e3181c8cbd9","article-title":"Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.","volume":"5","author":"JM Amann","year":"2010","journal-title":"J Thorac Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.lungcan.2009.11.019","article-title":"VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.","volume":"69","author":"DP Carbone","year":"2010","journal-title":"Lung Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/1055-9965.EPI-09-0937","article-title":"Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.","volume":"19","author":"CH Chung","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref37","article-title":"American Society of Clinical Oncology website."},{"key":"ref38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5","article-title":"Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging.","volume":"72","author":"C Boutin","year":"1993","journal-title":"Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e20199","DOI":"10.1371\/journal.pone.0020199","article-title":"Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung adenocarcinomas.","volume":"6","author":"PR Sudhir","year":"2011","journal-title":"PLoS One"},{"key":"ref40","first-page":"4682","article-title":"ras oncogenes in human cancer: a review.","volume":"49","author":"JL Bos","year":"1989","journal-title":"Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/14796694.5.1.105","article-title":"Isoform-specific ras functions in development and cancer.","volume":"5","author":"MP Quinlan","year":"2009","journal-title":"Future Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0165-4608(00)00223-5","article-title":"H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers.","volume":"121","author":"B Przybojewska","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.","volume":"16","author":"E Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.jid.5700026","article-title":"Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.","volume":"126","author":"VK Goel","year":"2006","journal-title":"J Invest Dermatol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1056\/NEJM199008303230902","article-title":"K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.","volume":"323","author":"RJ Slebos","year":"1990","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.bjc.6602258","article-title":"The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.","volume":"92","author":"C Mascaux","year":"2005","journal-title":"Br J Cancer"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H","article-title":"Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung.","volume":"92","author":"SA Ahrendt","year":"2001","journal-title":"Cancer"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1471-2407-10-189","article-title":"Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.","volume":"10","author":"N Van Damme","year":"2010","journal-title":"BMC Cancer"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V","article-title":"Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.","volume":"72","author":"C Boutin","year":"1993","journal-title":"Cancer"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1517\/14712590903002039","article-title":"Reovirus-based therapy for cancer.","volume":"9","author":"K Kelly","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"ref51","article-title":"National Cancer Institute website."},{"key":"ref52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1476-4598-9-188","article-title":"Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.","volume":"9","author":"X Zhang","year":"2010","journal-title":"Mol Cancer"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.","volume":"448","author":"M Soda","year":"2007","journal-title":"Nature"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.","volume":"131","author":"K Rikova","year":"2007","journal-title":"Cell"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.","volume":"115","author":"DW Wong","year":"2009","journal-title":"Cancer"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1245\/s10434-009-0808-7","article-title":"Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.","volume":"17","author":"T Takahashi","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.","volume":"363","author":"JE Butrynski","year":"2010","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.","volume":"27","author":"AT Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref59","article-title":"ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.","author":"JM Heuckmann","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1758834011408636","article-title":"The role of the c-Met pathway in lung cancer and the potential for targeted therapy.","volume":"3","author":"M Sattler","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/JTO.0b013e31819d6f91","article-title":"MET pathway as a therapeutic target.","volume":"4","author":"ES Kim","year":"2009","journal-title":"J Thorac Oncol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"e8972","DOI":"10.1371\/journal.pone.0008972","article-title":"CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.","volume":"5","author":"YH Tan","year":"2010","journal-title":"PLoS One"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.","volume":"65","author":"PC Ma","year":"2005","journal-title":"Cancer Res"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1615\/JEnvironPatholToxicolOncol.v28.i2.10","article-title":"MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.","volume":"28","author":"R Kanteti","year":"2009","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4161\/cam.4.1.10973","article-title":"MET molecular mechanisms and therapies in lung cancer.","volume":"4","author":"RE Lawrence","year":"2010","journal-title":"Cell Adh Migr"},{"key":"ref66","first-page":"6272","article-title":"c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.","volume":"63","author":"PC Ma","year":"2003","journal-title":"Cancer Res"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1158\/1078-0432.CCR-09-0070","article-title":"Ethnic differences and functional analysis of MET mutations in lung cancer.","volume":"15","author":"S Krishnaswamy","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1158\/1078-0432.CCR-09-1365","article-title":"Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.","volume":"16","author":"MS Gordon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lungcan.2010.04.008","article-title":"PI3K\/PTEN\/AKT\/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.","volume":"71","author":"X Pu","year":"2011","journal-title":"Lung Cancer"},{"key":"ref70","first-page":"4175","article-title":"Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.","volume":"29","author":"S Al-Saad","year":"2009","journal-title":"Anticancer Res"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1158\/0008-5472.CAN-07-5084","article-title":"PIK3CA mutations and copy number gains in human lung cancers.","volume":"68","author":"H Yamamoto","year":"2008","journal-title":"Cancer Res"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.lungcan.2009.11.012","article-title":"PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.","volume":"69","author":"G Jin","year":"2010","journal-title":"Lung Cancer"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1054\/bjoc.2001.1876","article-title":"Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells.","volume":"85","author":"GP Pidgeon","year":"2001","journal-title":"Br J Cancer"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1096\/fasebj.14.5.652","article-title":"Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line.","volume":"14","author":"A Biroccio","year":"2000","journal-title":"FASEB J"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/93.3.208","article-title":"Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.","volume":"93","author":"A Fernandez","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1096\/fj.02-0122fje","article-title":"Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity.","volume":"16","author":"A Iervolino","year":"2002","journal-title":"FASEB J"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S1010-7940(02)00112-4","article-title":"Small cell lung carcinoma (SCLC): the angiogenic phenomenon.","volume":"21","author":"M Lucchi","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref78","first-page":"6","article-title":"Expression of bcl-2 in small cell lung carcinoma cells.","volume":"54","author":"N Ikegaki","year":"1994","journal-title":"Cancer Res"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/path.1711770206","article-title":"Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas.","volume":"177","author":"SX Jiang","year":"1995","journal-title":"J Pathol"},{"key":"ref80","first-page":"1689","article-title":"Immunohistochemical detection of bcl2, p53, mdm2 and p21\/waf1 proteins in small-cell lung carcinomas.","volume":"18","author":"K Stefanaki","year":"1998","journal-title":"Anticancer Res"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/bjc.1998.624","article-title":"Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.","volume":"78","author":"U Zangemeister-Wittke","year":"1998","journal-title":"Br J Cancer"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours.","volume":"435","author":"T Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/0008-5472.CAN-06-2203","article-title":"Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.","volume":"67","author":"SK Tahir","year":"2007","journal-title":"Cancer Res"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"315","DOI":"10.6004\/jnccn.2008.0026","article-title":"Novel systemic therapies for small cell lung cancer.","volume":"6","author":"CM Rudin","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.2004.10.148","article-title":"Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.","volume":"22","author":"CM Rudin","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.neo.7900162","article-title":"Global methylation profiling of lung cancer identifies novel methylated genes.","volume":"3","author":"Z Dai","year":"2001","journal-title":"Neoplasia"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.","volume":"20","author":"LR Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.","volume":"27","author":"RL Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref89","first-page":"1327","article-title":"DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.","volume":"61","author":"WG Zhu","year":"2001","journal-title":"Cancer Res"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3816\/CLC.2009.n.037","article-title":"The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers.","volume":"10","author":"DR Camidge","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"ref91","article-title":"Clinical Significance of IGF1R Expression in Non-Small-Cell Lung Cancer.","author":"M Nakagawa","year":"2011","journal-title":"Clin Lung Cancer"},{"key":"ref92","article-title":"Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer.","author":"JS Kim","year":"2011","journal-title":"Cancer"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"abstr 7500","DOI":"10.1200\/jco.2010.28.15_suppl.7500","article-title":"Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).","volume":"28","author":"J Jassem","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2011.36.6799","article-title":"Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung Cancer.","volume":"29","author":"SS Ramalingam","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2008.19.9331","article-title":"Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.","volume":"27","author":"DD Karp","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref96","article-title":"Clinicaltrials.gov website."},{"key":"ref97","article-title":"Clinicaltrials.gov website."},{"key":"ref98","article-title":"Clinicaltrials.gov website."},{"key":"ref99","article-title":"Clinicaltrials.gov website."},{"key":"ref100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrclinonc.2010.64","article-title":"Targeted therapy in non-small-cell lung cancer\u2013is it becoming a reality?","volume":"7","author":"F Janku","year":"2010","journal-title":"Nat Rev Clin Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0031906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T02:29:36Z","timestamp":1561343376000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0031906"}},"subtitle":[],"editor":[{"given":"Surinder K.","family":"Batra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,21]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0031906","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,21]]}}}